Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
出版年份 2021 全文链接
标题
Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
作者
关键词
-
出版物
Protein & Cell
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-08
DOI
10.1007/s13238-020-00809-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
- (2020) Milton Packer DIABETES CARE
- Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors
- (2020) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Upregulation of Rubicon promotes autosis during myocardial ischemia/reperfusion injury
- (2020) Jihoon Nah et al. JOURNAL OF CLINICAL INVESTIGATION
- Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
- (2019) Rachel J. Perry et al. Nature Communications
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
- (2019) Michael E. Nassif et al. CIRCULATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming
- (2019) Angelo Avogaro et al. DIABETES CARE
- The Role of Autophagy in the Heart
- (2018) Sebastiano Sciarretta et al. Annual Review of Physiology
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- (2018) Lorenzo Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- New Insights Into the Role of mTOR Signaling in the Cardiovascular System
- (2018) Sebastiano Sciarretta et al. CIRCULATION RESEARCH
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction
- (2018) Sebastiano Sciarretta et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes
- (2018) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of glucose-lowering therapies on heart failure
- (2018) Michael Nassif et al. Nature Reviews Cardiology
- Cardioprotective effects of autophagy: Eat your heart out, heart failure!
- (2018) Gaetano Santulli Science Translational Medicine
- LncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardin transcription
- (2018) Cui-Yun Liu et al. Nature Communications
- SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
- (2018) Robert M Bell et al. Lancet Diabetes & Endocrinology
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
- (2018) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Myocardial stress and autophagy: mechanisms and potential therapies
- (2017) Lea M. D. Delbridge et al. Nature Reviews Cardiology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Empagliflozin’s Fuel Hypothesis: Not so Soon
- (2016) Gary D. Lopaschuk et al. Cell Metabolism
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor
- (2015) Y. Xiang et al. BLOOD
- Autophagy in cardiovascular biology
- (2015) Sergio Lavandero et al. JOURNAL OF CLINICAL INVESTIGATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- I-TASSER server: new development for protein structure and function predictions
- (2015) Jianyi Yang et al. NUCLEIC ACIDS RESEARCH
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Histone Deacetylase Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy
- (2014) Min Xie et al. CIRCULATION
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia
- (2013) Y. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury
- (2012) Satoru Kobayashi et al. Autophagy
- Cell Death in the Pathogenesis of Heart Disease: Mechanisms and Significance
- (2010) Russell S. Whelan et al. Annual Review of Physiology
- Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating Starvation-Induced Autophagy in Cardiac Myocytes
- (2010) Nirmala Hariharan et al. CIRCULATION RESEARCH
- Role of BNIP3 and NIX in cell death, autophagy and mitophagy
- (2009) J Zhang et al. CELL DEATH AND DIFFERENTIATION
- Activation of Na + /H + Exchanger 1 Is Sufficient to Generate Ca 2+ Signals That Induce Cardiac Hypertrophy and Heart Failure
- (2008) Tomoe Y. Nakamura et al. CIRCULATION RESEARCH
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started